Skip to main content

Oncimmune Signs Portugal Distribution Deal for Lung Cancer Dx

NEW YORK (360Dx) – UK diagnostics firm Oncimmune announced today that it has signed on Sabartech as the exclusive distributor of its lung cancer test EarlyCDT-Lung in Portugal.

The test, which was launched in the US in 2012, is designed to measure levels of seven auto-antibodies to tumor-associated antigens. According to Oncimmune, it can detect all forms of lung cancer at any stage.

Under the terms of the deal, Sabartech — which currently distributes EarlyCDT-Lung in Spain — will offer the test in Portugal, with a minimum sales commitment of £700,000 ($911,619) over five years. The companies have also extended Sabartech's Spanish distribution deal to five years from three years, adding an additional £1.8 million of minimum sales commitments over the final two years of the arrangement.

"Portugal and Spain are important European markets and Sabartech has made good progress so far including selling EarlyCDT-Lung for screening through Quirónsalud, the largest private hospital network in Spain," Oncimmune CEO Adam Hill said in a statement. "Extending our relationship to include Portugal was a natural progression and marks another step in the commercialization of EarlyCDT-Lung."

In 2017, Oncimmune licensed the Israeli and South Korean distribution rights to EarlyCDT-Lung to Best Medical Opinion and Dow Biomedica/Biodiscovery, respectively. And last month, the firm acquired Protagen Diagnostics for up to £4.1 million.